Xyloglucan based mucosal nanovaccine for immunological protection against brucellosis developed by supercritical fluid technology

Vaccines delivered via the mucosal route have logistic benefits over parenteral or intramuscular vaccines as they offer patient compliance. This study presents the first intranasal, controlled release, subunit nanovaccine comprising mucoadhesive tamarind seed polymer (xyloglucan) based nanoparticles...

Descripción completa

Detalles Bibliográficos
Autores principales: Vyas, Swati, Dhoble, Sagar, Ghodake, Vinod, Patravale, V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7397708/
https://www.ncbi.nlm.nih.gov/pubmed/32776000
http://dx.doi.org/10.1016/j.ijpx.2020.100053

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7397708/
https://www.ncbi.nlm.nih.gov/pubmed/32776000
http://dx.doi.org/10.1016/j.ijpx.2020.100053

Ejemplares similares